Min Wang
President chez Ensoma, Inc.
Profil
Min Wang is currently the Director at Lacerta Therapeutics, Inc. and also holds the position of President & Chief Operating Officer at Ensoma, Inc. Previously, Dr. Wang worked as Senior Patent Counsel at Genentech, Inc. and as Associate at Fish & Neave LLP.
Dr. Wang also served as Senior Vice President & General Counsel at Agios Pharmaceuticals, Inc. and as Chief Operating Officer at BlueRock Therapeutics Canada ULC and BlueRock Therapeutics LP.
Additionally, Dr. Wang was the Chief Operating Officer at Monte Rosa Therapeutics, Inc. from 2020 to 2021.
Dr. Wang holds a doctorate degree from Brown University, an undergraduate degree from Salem State University, and a graduate degree from Fordham University School of Law.
Postes actifs de Min Wang
| Sociétés | Poste | Début |
|---|---|---|
Lacerta Therapeutics, Inc.
 Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Directeur/Membre du Conseil | 24/11/2021 |
Ensoma, Inc.
 Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | President | - |
Anciens postes connus de Min Wang
| Sociétés | Poste | Fin |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Directeur des opérations | 01/02/2021 |
| AGIOS PHARMACEUTICALS, INC. | Conseiller Juridique Général | 01/11/2018 |
BlueRock Therapeutics LP
 BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Directeur des opérations | - |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Directeur des opérations | - |
Fish & Neave LLP
 Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Fish & Neave operates as a law firm. It specializes in specializes in intellectual property issues involving patents, trademarks, and copyrights. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Min Wang
| Salem State University | Undergraduate Degree |
| Brown University | Doctorate Degree |
| Fordham University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Fish & Neave LLP
Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Fish & Neave operates as a law firm. It specializes in specializes in intellectual property issues involving patents, trademarks, and copyrights. The company is headquartered in New York, NY. | Commercial Services |
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Health Technology |
BlueRock Therapeutics LP
BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Commercial Services |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
